Screener
Beam Therapeutics BEAM Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $12,286 | $10,231 |
| Accrued expenses and other current liabilities | 39,291 | 55,267 |
| Current portion of derivative liabilities | 5,200 | 7,700 |
| Current portion of deferred revenue | 304 | 6,659 |
| Current portion of lease liability | 14,781 | 14,364 |
| Current portion of contingent consideration liabilities | 2,703 | 2,714 |
| Total current liabilities | 74,565 | 96,935 |
| Long-term lease liability | 135,848 | 139,759 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's deferred revenue?
- Beam Therapeutics (BEAM) reported deferred revenue of $304K in Q1 2026.
- How has Beam Therapeutics's deferred revenue changed year-over-year?
- Beam Therapeutics's deferred revenue decreased by 99.6% year-over-year, from $85.2M to $304K.
- What is the long-term trend for Beam Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), Beam Therapeutics's deferred revenue has grown at a 208.1% compound annual growth rate (CAGR), from $24K to $6.66M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Beam Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude